Posters

Home / Resources / Posters Poster Advancing mast cell research with a standardized human primary cell platform Chenyan Wu1, Cyprien Pecalvel1, Anthony David1 and Nicolas Gaudenzio1,2 1Genoskin SAS, 2INSERM UMR1291 - CNRS UMR5051, University Toulouse III Understanding mast cell activation in a human-relevant context Mast cells play a central role in immune regulation, inflammation and allergic responses, making them highlyRead more

Home / Resources / Posters Poster A drug development platform for immunogenicity and toxicity assessment using advanced multi-omic profiling Manon Scholaert1,2, Mathias Peries2, Emilie Braun2, Alexandra Ochando3, Emeline Pagès2 and Nicolas Gaudenzio1,2 1Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 - CNRS UMR5051 - University Toulouse III, France, 2Genoskin SAS, Toulouse, France, 3Genoskin Inc, Salem MA, USA LongitudinalRead more

Home / Resources / Posters Poster Human primary mast cells as an advanced model for drug development Chenyan Wu1, Anthony David1, Anne Dalapa-Amana1, Catherine Marques1, Alexandra Ochando2, Lorna Santos2 and Nicolas Gaudenzio3 1Genoskin SAS, Toulouse, France, 2Genoskin Inc, Salem MA, USA, 3Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 - CNRS UMR5051 - University Toulouse III, France ARead more

Home / Resources / Posters Poster Replacing animal testing in local tolerance assessment of an injection device: Human ex vivo HypoSkin® model as a New Approach Methodology (NAM) Jérémy Argenty1, Clémence Letzelter1, Catherine Marques1, Sophie Abadie1, Alexia Sanchez1, Claire Gendrin1, Alexandra Ochando1, Adam Rock2, Ronan Byrne2, Pascal Descargues1 and Nicky Bertollo2 1Genoskin, 2Pharma Latch HypoSkin® is an ex vivo human skin NAM thatRead more

Home / Resources / Posters Poster HypoSkin® as a human-based NAMs platform for local toxicity and formulation safety assessment Julie Magerman1, Katarzyna Polak2, Ornella Binazon1, Michael Pastore2, Alexandra Ochando2 and Judith Baumeister1 1argenx, 2Genoskin Local Toxicity and Formulation Safety: An argenx Collaboration Study Formulation safety testing still relies heavily on in vivo studies due to limited validated in vitro alternatives. Genoskin’s HypoSkin® biostabilized ex vivo human skinRead more

Prove ADCC Activityin real human skinFor therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential.Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear. HypoSkin® offers a solution Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm theRead more